Australia's most trusted
source of pharma news
Posted 7 August 2025 AM
New indications for semaglutide are being touted even as competing GLP-1RAs enter the weight loss arena and generics of the drug circle, with the latest efforts looking at cerebrovascular disease management.
Recent clinical findings suggest semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, is a promising candidate for neurological conditions, with key opinion leaders saying the potential in brain diseases seems to be based on its anti-inflammatory action.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.